Skip to content

BioRICS

Active Public limited companyfounded 2006active for 20 yearsTechnologielaan 3, 3001 LeuvenKBO/BCE: BE 0880.194.826

Board

2 directors, no change since 2024
Director
current term since 06-06-2024 term until 10-05-2027
listed in the 2025 annual accounts, filed on 07-08-2026
Director
since 06-06-2024 term until 10-05-2027
listed in the 2025 annual accounts, filed on 07-08-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“Bijzondere opdrachten De raad van bestuur is gemachtigd bijzondere gemachtigden en/of bestuurders te gelasten met bijzondere opdrachten, en…”
deed of 17-03-2021

Office holders in the KBO →

Mandates through the years

12 names, the dashed line is today

Director

Director

Director

Director

Director

Director

Director

Director

Managing director

Director

Director

Director
BoardEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
    • Director, appointed by deed of 29-08-2013, until 17-03-2021
    • Director, appointed by deed of 04-09-2024, still in office
    • Director, since before 26-10-2017
    • Director, appointed by deed of 23-11-2020, until 17-03-2021
    • Managing director, appointed by deed of 09-06-2021, ended, last mentioned on 09-06-2021
    • Director, until 04-09-2024
    • Director, appointed by deed of 17-03-2021, until 02-08-2023
    • Chair of the board, appointed by deed of 09-06-2021, ended, last mentioned on 09-06-2021
    • Director, from before 15-06-2010 to 17-03-2021
    • Chair of the board, appointed by deed of 23-03-2011, ended, last mentioned on 23-03-2011
    • Director, appointed by deed of 26-10-2017, until 17-03-2021
    • Director, appointed by deed of 23-11-2020, no longer listed in the 2025 annual accounts
    • Director, appointed by deed of 23-03-2011, until 26-10-2017
    • Director, from before 15-06-2010 to 29-08-2013
    • Managing director, appointed by deed of 23-03-2011, until 29-08-2013
    • Director, from before 14-11-2012, no longer listed in the 2025 annual accounts
    • Director, from before 15-06-2010 to 04-07-2011
    • Managing director, from before 15-06-2010 to 22-02-2011
    • Chair of the board, from before 15-06-2010, ended, last mentioned on 23-09-2010
    • Director, from before 15-06-2010 to 22-02-2011

Control

Shareholder
Equity €1.35bn
Profit €67.8m in 2025 (loss €10.2m in 2024)
Source: accounts 2025
23.82%
This company
BioRICS
Equity -€104,780
Loss €194,737 in 2025

Capital

Capital
€1,350,000
Shares
6,344,415 in the deed of 17-03-2021
Source
deed of 06-07-2022

Owners through the years

as the annual accounts name them
23.82%
4.69% until 2017
26.55% until 2011
Owners as a list
    • 2021: 28.71%
    • 2022 to 2025: 23.82%
    • 2012: 21.5%
    • 2013 to 2017: 4.69%
    • 2011: 26.55%

Source: lists of holdings in the owners' accounts

Articles of association

DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 17-03-2021 (in Dutch)
Board ruleThese rules set how the board is made up, meets and takes decisions.
Term of at most 6 years
deed of 17-03-2021 (in Dutch)
Power of attorneyA power of attorney lets someone perform specific acts on the company's behalf.
“”
deed of 09-06-2021 (in Dutch)
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Second Monday of May at 17:00
deed of 04-09-2024 (in Dutch)
Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
“Algemene vergadering bepaalt vergoeding, bij deficitaire vereffening ter bevestiging aan voorzitter bevoegde rechtbank”
deed of 17-03-2021 (in Dutch)

Capital transactions

Shareholders according to the deeds
After 3 capital increases deed of 17-03-2021 ↗
  • 364,273 shares
  • 364,273 shares
Capital over time
  1. 06-07-2022 Capital reduction · to €1,350,000
  2. 17-03-2021 Capital increase of €1,500,000 · to €1,900,000 · 1,821,363 new shares at €0.82 per share · in cash
  3. 17-03-2021 Capital increase of €600,000 · to €2,500,000 · 728,546 new shares, 11.5% of the 6,344,415 shares after the increase · in kind
  4. 17-03-2021 Capital increase of €3 · to €2,500,003 · 1,303,376 new shares, 17% of the 7,647,791 shares after the increase
  5. 14-01-2021 Capital reduction of €1,170,368.24 · to €400,000
  6. 13-05-2020 Capital increase of €562,500 · to €1,570,368.24 · 1,366,021 new shares at €0.41 per share, 36% of the 3,794,506 shares after the increase · in cash
  7. 04-12-2017 Capital increase of €249,051.24 · to €1,007,868.24 · 469,908 new shares, 19.3% of the 2,428,485 shares after the increase
  8. 26-10-2017 Capital increase of €250,000 · at €0.53 per share · in cash
Show 7 older capital entries
  1. 26-10-2017 Capital increase of €250,000 · at €1.33 per share · in cash
  2. 25-05-2016 Capital increase of €500,000 · to €758,817 · 195,000 new shares, 10.4% of the 1,879,630 shares after the increase · in cash
  3. 17-11-2011 Capital increase of €85,000 · to €198,817 · 772,729 new shares at €0.11 per share · in cash
  4. 17-11-2011 Capital increase of €60,000 · to €258,817 · 545,455 new shares at €0.11 per share, 32.4% of the 1,684,630 shares after the increase · “conversie van obligaties”
  5. 02-09-2011 Capital reduction of €252,629 · to €113,817 · “zonder vernietiging van aandelen”
  6. 01-04-2011 Capital increase · 150,000 new shares
  7. 21-12-2010 Capital increase of €116,446 · to €366,446 · 116,446 new shares at €1 per share, 31.8% of the 366,446 shares after the increase · uitoefening warrants

Next steps